Aeterna Zentaris (AEZS) announced that sales of Macrilen will be temporarily discontinued in the United States commercial market for the diagnosis of adult growth hormone deficiency, effective May 23, 2023 and until anticipated re-launch with an alternate commercialization partner. This temporary action follows the August 29, 2022 announced decision by Aeterna’s former North American commercialization partner Novo Nordisk Healthcare (NVO) to end its license agreement for this product in North America. The Company is actively seeking alternate development and commercialization partners for Macrilen in the US and other territories currently not partnered. The decision to temporarily discontinue sales of Macrilen in the United States does not have any impact on the sales and commercialization efforts in the UK and European Economic Area. On March 16, 2023, Aeterna announced that Pharmanovia, a global lifecycle management healthcare company, had acquired the exclusive rights and license to commercialize GHRYVELIN in the territory for the diagnosis of Adult Growth Hormone Deficiency and, if approved, for Childhood Onset Growth Hormone Deficiency from the Company’s previous EEA and UK partner, Consilient Health.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AEZS:
- Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
- Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
- Aeterna Zentaris reports Q4 revenue $2.5M vs. $1M last year
- Aeterna Zentaris announces Pharmanovia has acquired rights to GHRYVELIN
- Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)